Drug intelligence / Profile preview

TER-2013

Development stage: Phase 2
Lead developer: Terremoto Biosciences
Modality: Small Molecules

Overview

TER-2013 is an investigational drug currently undergoing a Phase 1/2, open-label, multicenter clinical trial. This first-in-human study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of TER-2013 in patients with advanced solid tumors that harbor alterations in the AKT/PI3K/PTEN pathway. The drug is being assessed both as a monotherapy and in combination with fulvestrant, with the trial structured into a dose escalation part and a dose expansion part to determine the maximum tolerated/administered dose and preliminary clinical activity.

Targets

PI3K (Phosphoinositide-3-kinase regulatory subunit 6)AKT (RAC-alpha serine/threonine-protein kinase)

Beyond the preview

Go deeper on TER-2013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TER-2013.

Explore the full profile